Chapter 26 - Drugs and Cosmetics.
- Article 1 - General Provisions, 26-1-1 through 26-1-26.
- Section 26-1-1 - Short title.
- Section 26-1-10 - Drug or device adulteration.
- Section 26-1-11 - Drug or device; misbranding.
- Section 26-1-12 - False advertising.
- Section 26-1-13 - Packaging and labeling requirements; proprietary preparations.
- Section 26-1-14 - New drugs; prerequisites to sale, delivery or giving away; exceptions.
- Section 26-1-15 - Dangerous drugs; veterinary use; limitations.
- Section 26-1-16 - Dangerous drugs; conditions for sale; prescription refilling; limitations.
- Section 26-1-17 - Testing laboratory.
- Section 26-1-18 - Promulgating regulations; procedure.
- Section 26-1-19 - Power to make inspections and secure samples.
- Section 26-1-2 - Definitions.
- Section 26-1-20 - Personnel.
- Section 26-1-21 - Power of board to publish reports and disseminate information.
- Section 26-1-22 - Unlawful means of obtaining dangerous drugs enumerated.
- Section 26-1-23 - False statements; false pretenses; forgery of labels or prescriptions prohibited.
- Section 26-1-24 - Cosmetics; misbranding.
- Section 26-1-25 - Cosmetics; adulteration.
- Section 26-1-26 - Penalties.
- Section 26-1-3 - Prohibited acts.
- Section 26-1-3.1 - Repealed.
- Section 26-1-4 - Power to enjoin violations.
- Section 26-1-5 - Penalty; exemptions.
- Section 26-1-6 - Detection of drugs, devices or cosmetic believed adulterated, misbranded or counterfeit; condemnation; destruction or correction of defect; forfeiture and sale.
- Section 26-1-7 - Attorney general or district attorney to institute prosecutions.
- Section 26-1-8 - Minor violations of act; warnings authorized.
- Section 26-1-9 - Addition of poisonous or deleterious substances; color additives.
- Article 2 - Drug Abuse, 26-2-1 through 26-2-14.
- Article 2A - Controlled Substances Therapeutic Research, 26-2A-1 through 26-2A-7.
- Section 26-2A-1 - Short title.
- Section 26-2A-2 - Purpose.
- Section 26-2A-3 - Definitions.
- Section 26-2A-4 - Lynn Pierson therapeutic research program established; participation.
- Section 26-2A-5 - Patient qualification review board; composition; powers and duties.
- Section 26-2A-6 - Lynn Pierson therapeutic research program; distribution.
- Section 26-2A-7 - Report.
- Article 2B - Lynn and Erin Compassionate Use Act, 26-2B-1 through 26-2B-7.
- Section 26-2B-1 - Short title.
- Section 26-2B-2 - Purpose of act.
- Section 26-2B-3 - Definitions.
- Section 26-2B-4 - Exemption from criminal and civil penalties for the medical use of cannabis.
- Section 26-2B-5 - Prohibitions, restrictions and limitations on the medical use of cannabis; criminal penalties.
- Section 26-2B-6 - Advisory board created; duties.
- Section 26-2B-7 - Registry identification cards; department rules; duties.
- Article 3 - Drug Product Selection, 26-3-1 through 26-3-3.